Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Denton

Showing results (251-260 of 484) with videos related to

Pageof 49
Sort By:
Plos One|July 18, 2019
Stem cell enriched lipotransfer reverses the effects of fibrosis in systemic sclerosisAurora Almadori, Michelle Griffin, Caroline M Ryan, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 21, 2017
Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic SclerosisNicole S Goh, Rachel K Hoyles, Christopher P Denton, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 2, 2017
Association of Defective Regulation of Autoreactive Interleukin-6-Producing Transitional B Lymphocytes With Disease in Patients With Systemic SclerosisTaher E Taher, Voon H Ong, Jonas Bystrom, et al.
Annals of the Rheumatic Diseases|July 2, 2014
Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR databaseBritta Maurer, Nicole Graf, Beat A Michel, et al.
Cells|April 26, 2024
Exploring Anti-Fibrotic Effects of Adipose-Derived Stem Cells: Transcriptome Analysis upon Fibrotic, Inflammatory, and Hypoxic ConditioningMarvin L Frommer, Benjamin J Langridge, Alexandra Beedie, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 31, 2025
Serum Type I Interferon Score for Prediction of Clinically Meaningful Disease Progression in Limited Cutaneous Systemic SclerosisStefano Di Donato, Rebecca Ross, Ranjitha Karanth, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|July 15, 2024
Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosisElizabeth R Volkmann, Christopher P Denton, Martin Kolb, et al.
American Journal of Respiratory and Critical Care Medicine|December 1, 2021
Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled TrialDinesh Khanna, Celia J F Lin, Daniel E Furst, et al.
Current Medical Research and Opinion|July 23, 2019
Progressive fibrosing interstitial lung diseases: current practice in diagnosis and managementMarlies Wijsenbeek, Michael Kreuter, Amy Olson, et al.
Arthritis and Rheumatism|December 1, 2007
Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblastsXu Shi-wen, Laura Kennedy, Elisabetta A Renzoni, et al.
Pageof 49

Showing results (251-260 of 484) with videos related to

Sort By:
Pageof 49
Plos One|July 18, 2019
Stem cell enriched lipotransfer reverses the effects of fibrosis in systemic sclerosisAurora Almadori, Michelle Griffin, Caroline M Ryan, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 21, 2017
Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic SclerosisNicole S Goh, Rachel K Hoyles, Christopher P Denton, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 2, 2017
Association of Defective Regulation of Autoreactive Interleukin-6-Producing Transitional B Lymphocytes With Disease in Patients With Systemic SclerosisTaher E Taher, Voon H Ong, Jonas Bystrom, et al.
Annals of the Rheumatic Diseases|July 2, 2014
Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR databaseBritta Maurer, Nicole Graf, Beat A Michel, et al.
Cells|April 26, 2024
Exploring Anti-Fibrotic Effects of Adipose-Derived Stem Cells: Transcriptome Analysis upon Fibrotic, Inflammatory, and Hypoxic ConditioningMarvin L Frommer, Benjamin J Langridge, Alexandra Beedie, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 31, 2025
Serum Type I Interferon Score for Prediction of Clinically Meaningful Disease Progression in Limited Cutaneous Systemic SclerosisStefano Di Donato, Rebecca Ross, Ranjitha Karanth, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|July 15, 2024
Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosisElizabeth R Volkmann, Christopher P Denton, Martin Kolb, et al.
American Journal of Respiratory and Critical Care Medicine|December 1, 2021
Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled TrialDinesh Khanna, Celia J F Lin, Daniel E Furst, et al.
Current Medical Research and Opinion|July 23, 2019
Progressive fibrosing interstitial lung diseases: current practice in diagnosis and managementMarlies Wijsenbeek, Michael Kreuter, Amy Olson, et al.
Arthritis and Rheumatism|December 1, 2007
Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblastsXu Shi-wen, Laura Kennedy, Elisabetta A Renzoni, et al.
Pageof 49